Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other financing activities (2016 - 2018)

Vanda Pharmaceuticals (VNDA) has disclosed Other financing activities for 7 consecutive years, with $2.7 million as the latest value for Q1 2018.

  • Quarterly Other financing activities rose 20.69% to $2.7 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Mar 2018, down 42.55% year-over-year, with the annual reading at $5.3 million for FY2017, 32.25% down from the prior year.
  • Other financing activities hit $2.7 million in Q1 2018 for Vanda Pharmaceuticals, up from $81000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $5.9 million in Q3 2016 to a low of -$2.0 million in Q3 2014.
  • Historically, Other financing activities has averaged $1.0 million across 5 years, with a median of $671000.0 in 2015.
  • Biggest YoY gain for Other financing activities was 122300.0% in 2014; the steepest drop was 240.1% in 2014.
  • Year by year, Other financing activities stood at -$2.0 million in 2014, then surged by 100.05% to $1000.0 in 2015, then surged by 74900.0% to $750000.0 in 2016, then plummeted by 89.2% to $81000.0 in 2017, then surged by 3191.36% to $2.7 million in 2018.
  • Business Quant data shows Other financing activities for VNDA at $2.7 million in Q1 2018, $81000.0 in Q4 2017, and $768000.0 in Q3 2017.